Phase 3 Clinical Trials With Primary Completion Dates in November 2022
This is a list of Phase 3 trials with primary completion dates in November 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 2022-11-01 | Phase 3 | NCT04142658 | PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban |
| APLT | Applied Therapeutics, Inc. | 2022-11-01 | Phase 3 | NCT05418829 | AT-007 in Adult Subjects With Classic Galactosemia (CG) |
| BLUE | bluebird bio, Inc. | 2022-11-01 | Phase 3 | NCT03207009 | A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia |
| CORT | Corcept Therapeutics Incorporated | 2022-11-01 | Phase 3 | NCT03697109 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome |
| GLPG | Galapagos NV | 2022-11-01 | Phase 3 | NCT02914561 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease |
| KRTX | Karuna Therapeutics, Inc. | 2022-11-01 | Phase 3 | NCT04738123 | A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) |
| LIAN | LianBio | 2022-11-01 | Phase 3 | NCT05174416 | A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM |
| NWBO | Northwest Biotherapeutics, Inc. | 2022-11-01 | Phase 3 | NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer |
| PHAT | Phathom Pharmaceuticals, Inc. | 2022-11-01 | Phase 3 | NCT05195528 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) |
| PRTK | Paratek Pharmaceuticals, Inc. | 2022-11-01 | Phase 3 | NCT04779242 | Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia |
| RYTM | Rhythm Pharmaceuticals, Inc. | 2022-11-01 | Phase 3 | NCT05194124 | A Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway |
| SYNH | Syneos Health, Inc. | 2022-11-01 | Phase 3 | NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| VAXX | Vaxxinity, Inc. | 2022-11-01 | Phase 3 | NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |